ESSEX BIO-TECH (01061) announced on September 1 that it allocated HK$129,900 to repurchase 60,000 of its shares.
The buyback was executed at a total cost of HK$129,900, as part of the company's ongoing capital management strategy.
The repurchase underscores the company's confidence in its financial position and long-term growth prospects.